Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.

Vaccine - 21 Jun 2002

Gyotoku T, Ono F, Aurelian L

Abstract excerpt

A growth compromised herpes simplex virus type 2 (HSV-2) mutant which is deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10DeltaPK) protects from HSV-2 challenge in the mouse and guinea pig cutaneous and vaginal models and reduces the incidence and frequency of recurrent disease (Vaccine (17) (1999) 1951; Vaccine (19) (2001) 1879). The present studies were designed to identify the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Defective Viruses
Share to Herpes Genitalis
Share to Herpesvirus 2, Human

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunization

Share to Interleukin-12

Share to Ribonucleotide Reductases

Share to Th1 Cells

Share to Viral Vaccines

Source

Identifiers

PMID: 12034107
DOI: 10.1016/s0264-410x(02)00199-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.PMID 12034107Read ↗

A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.Semantic proximity Read ↗

Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease.Semantic proximity Read ↗

Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.Semantic proximity Read ↗

Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.Semantic proximity Read ↗

Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.Semantic proximity Read ↗

A Novel DNA Vaccine Technology Conveying Protection against a Lethal Herpes Simplex Viral Challenge in MiceSemantic proximity Read ↗

An Engineered Herpesvirus Activates Dendritic Cells and Induces Protective Immunity.Semantic proximity Read ↗

A Live-Attenuated HSV-2 ICP0− Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit VaccineSemantic proximity Read ↗

Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.Semantic proximity Read ↗

Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.Semantic proximity Read ↗

Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs.Semantic proximity Read ↗

A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.